UK markets closed

Santhera Pharmaceuticals Holding AG (0QN1.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
0.5670-0.0070 (-1.22%)
At close: 03:46PM GMT
Full screen
Previous close0.5740
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.0000 - 0.0000
52-week range
Avg. volumeN/A
Market cap64,530
Beta (5Y monthly)1.15
PE ratio (TTM)N/A
EPS (TTM)-1.6250
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Santhera’s Shareholders Approve all Board Proposals at Today’s Extraordinary General Meeting

    Pratteln, Switzerland, November 29, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders have approved all proposals by the Board of Directors at the Extraordinary General Meeting (EGM) held today at the Company’s domicile in Pratteln, Switzerland. In total, 18,776,400 shares equaling 25.5% of the Company’s share capital were represented. “With regulatory filings for vamorolone now submitted to the US FDA and European CHMP, the approval of an ordinary capital increase and

  • Globe Newswire

    Santhera Calls Extraordinary General Meeting to Seek Approval for Further Financings

    Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, November 4, 2022 – Santhera Pharmaceuticals (SIX: SANN) provides an update on its activities and is calling an Extraordinary General Meeting (EGM), which will be held on November 29, 2022, at 10:30 hrs at the domicile of the Company. At the EGM, Santhera seeks authorization for additional funding to enable continued pipeline development and preparations for the commercialization of vamorolone. Funding OutlookAs announced earlier,

  • Globe Newswire

    European Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

    Pratteln, Switzerland, October 31, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD). Validation confirms that the submission is complete and that the review by the EMA’s Committee for Medicinal Products for Human Use (CHMP) has begun. “The initiation of the CHMP review of our application is an important milestone for patie